Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Trial details
- Registry ID
- NCT05678673
- Phase
- Phase 3
The FDA approved Sunitinib Malate (Sutent®) on 26 Jan 2006.
Drug identity checked against registry records
Also recorded as Sutent®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaNCT05678673 | Exelixis | Phase 3 | Active not recruiting | 2026-12-15Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2006-01-26Day | Sunitinib Malate | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021938", "applicant_as_listed_by_fda": "CPPI CV", "brand_names": ["SUTENT"], "active_ingredients": ["SUNITINIB MALATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20060126", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |